NCT06435910Not yet recruitingPhase 1
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Engineered Dendritic Cell Vaccines for Remission Maintenance in Multiple Myeloma Patients
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 14 May 2024
- Start date
- 30 Jun 2027
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Shenzhen Geno-Immune Medical Institute
- Diseases
- Multiple myeloma
- NCT number
- NCT06435910
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 10
- From 30 Jun 2027 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent use of systemic steroids; the use of inhaled steroids is not exclusionary
Other illness
- Uncontrolled active infection
- HIV or active hepatitis B or hepatitis C infection
Other
- Pregnant or lactating women
Who the study is looking for
- Male and female subjects with multiple myeloma or plasmacytoma
- Very good partial or complete remission (CR) after prior combination therapies.
- Expected survival \> 12 weeks
- Adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal
- Voluntary informed consent is given with willingness to continue follow up
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shenzhen Geno-immune Medical Institute Coordinator of this site? Confirm its status | Shenzhen | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.